Regulatory press release

Immunovia AB announces outcome of exercise of warrants series TO 3

The exercise period for warrants series TO 3 (the “Warrant Programme”) in Immunovia AB (publ) (“Immunovia” or the “Company”) ended on 15 April 2025. A total of 44,174,217 warrants were exercised for the subscription of 44,174,217 new shares, corresponding to an exercise rate of approximately 71.0 percent.

Jeff Borcherding, CEO of Immunovia, comments:

“I want to extend a sincere thank you to all investors who chose to exercise their warrants of series TO 3. Your continued trust and support are deeply appreciated. This funding is an important step as we prepare for the commercial launch of our pancreatic cancer test — a milestone that brings us closer to delivering critical innovation to patients and healthcare providers”.

The exercise period for the Warrant Programme took place during the period 1 – 15 April 2025. One (1) warrant series TO 3 entitled the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 0.24 per share. A total of 44,174,217 warrants were exercised, corresponding to approximately 71.0 percent of the Warrant Programme, for the subscription of a total of 44,174,217 shares. Through the exercised warrants, Immunovia will thus receive a total of approximately 10.6 MSEK before issue costs.

Through the warrant exercise, the number of shares in Immunovia increases by 44,174,217 shares, from a total of 261,908,863 shares to 306 083 080 shares. The share capital increases by SEK 1,325,226.51 to SEK 9,182,492.40. For existing shareholders who have not exercised any warrants, the dilution amounts to approximately 14.4 percent based on the number of shares in Immunovia after the exercise of warrants.

Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted into shares within approximately two (2) weeks.

Advisers
Vator Securities AB acts as financial adviser and Setterwalls Advokatbyrå AB as legal adviser to Immunovia in connection with the exercise of the Warrant Programme. Vator Securities AB also acts as the issuing agent.

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.

IMPORTANT INFORMATION
The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Immunovia. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in Immunovia has only been made through the prospectus published by Immunovia on 12 August 2024. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company’s website, www.immunovia.com.

Since Immunovia is deemed to carry out protection-worthy activities according to the Swedish Screening of Foreign Direct Investments Act, the exercise of warrants for subscription of shares may require review by the Inspectorate of Strategic Products. More information about this can be found on the Company’s website, www.immunovia.com.